APhA needs your assistance to ensure you can effectively care for you patients. Reach out to your Member of Congress and Senators and ask them to take immediate action to provide adequate, appropriate, and fair payment for pharmacist consultations and services for prescribing Paxlovid.
We’re excited to announce the launch of the new APhA Learning Library! This new platform will make it easier than ever for you to get the education you need. Read about some key highlights of our new system.
APhA is committed to facilitating meaningful dialogue between pharmacy management, pharmacy team members, and other stakeholders that result in improved workplaces, well-being, and ability to meet ethical obligations to patient safety.
Tools and resources to support your practice
APhA’s monthly Pulse on Practice and Policy Open Forum Series creates a platform where all of pharmacy can come together to share perspectives and be informed of key practices and policies impacting the profession.
An APhA member-only resource for pharmacists, pharmacy residents, student pharmacists, pharmacy technicians, and interprofessional health care team members involved in providing transitions of care (TOC) services.
An outline of the key steps to implementing monoclonal antibody therapy administration services in community settings.
View CEO Blog
A letter from Interim CEO Ilisa Bernstein, PharmD, JD, FAPhA, to Dr. Robert Califf, Commissioner of the Food and Drug Administration (FDA), on the importance of pharmacists being allowed to prescribe oral COVID-19 treatments.
View all press releases
CARSON CITY, NV, and WASHINGTON, DC—The Nevada Pharmacy Alliance (NPA) and the American Pharmacists Association (APhA) are proud to announce that Nevada pharmacists can now bill the state’s Medicaid program for certain health care services.
View all news
Researchers at NYU Grossman School of Medicine say 86.6% of people living with opioid use disorder (OUD) in the United States are not receiving medications proven to reduce opioid overdoses, including methadone, buprenorphine, and extended-release naltrexone. Their study, published in International Journal of Drug Policy, looked at differences between new estimates of OUD prevalence and the use of medications for OUD (MOUD) at the national and state levels from 2010 to 2019.
Drug companies are asking for lofty prices for new medications coming to market, a Reuters analysis finds, often while disclosing little pricing information about the treatments.